MELBOURNE, AUSTRALIA – As Australia continues to emerge as one of the world’s most closely watched psychedelic medicine markets, a new industry symposium aims to bring together the psychiatrists, clinicians, researchers, investors and decision-makers helping shape the future of the sector.
The inaugural Psychedelic Roundtable Symposium 2027 (PRS27), presented by Psychedelics.Media, will take place in Melbourne on Saturday, 20 March 2027, bringing together key stakeholders from across psychiatry, psychology, neuroscience, healthcare, biotechnology, investment, media and public policy for a day of discussion, learning and collaboration.
At a time when psychedelic-assisted therapies are moving from clinical trials into real world healthcare settings, organisers believe there has never been a greater need for meaningful dialogue between the individuals and organisations responsible for building the future of the industry.
Australia’s decision to permit authorised psychiatrists to prescribe MDMA-assisted therapy for post traumatic stress disorder and psilocybin-assisted therapy for treatment-resistant depression has positioned the country at the forefront of one of the most significant developments in modern mental healthcare. Researchers, clinicians, regulators and investors from around the world are now closely watching how Australia’s regulatory framework evolves and what lessons can be learned from the implementation of psychedelic-assisted therapies in clinical practice.
PRS27 has been created to provide a forum where these conversations can occur openly, professionally and constructively.
A Forum for the Entire Ecosystem
Unlike traditional conferences that focus heavily on exhibitions and product promotion, PRS27 has been designed as a high level industry forum focused on discussion, collaboration and practical outcomes.
The symposium will bring together psychiatrists, psychologists, researchers, neuroscientists, healthcare operators, biotechnology executives, investors, academics, policymakers and regulators to examine the opportunities and challenges facing the psychedelic medicines sector.
Topics expected to be explored include:
- Clinical Implementation & Psychedelic Psychiatry
- Research, Evidence & Therapeutic Innovation
- Training & Workforce Development
- Regulation, Policy & Governance
- Patient Access & Healthcare Delivery
- Drug Development & Biotechnology
- Investment & Industry Growth
- Ethics, Standards & Safety
- Digital Health & Artificial Intelligence
- The Future of Psychedelic Medicine
By bringing together stakeholders from across multiple disciplines, organisers hope to encourage conversations that move beyond theory and towards practical solutions capable of advancing the sector responsibly.
Why Australia Matters
Australia occupies a unique position within the global psychedelic medicine landscape.
While much of the early research and investment activity has emerged from North America and Europe, Australia has become one of the first countries in the world to establish a regulated pathway for psychedelic-assisted therapies.
This places Australian clinicians, healthcare providers and regulators at the forefront of implementation and provides a unique opportunity for international delegates to gain insight into one of the world’s most closely watched psychedelic medicine environments.
As governments and healthcare systems continue to evaluate psychedelic-assisted therapies globally, the experiences and lessons emerging from Australia may help shape future policy and clinical practice in other jurisdictions.
The Business of Psychedelics
One of the defining themes of PRS27 will be the recognition that psychedelic medicine is both a healthcare movement and an emerging industry.
Scientific breakthroughs alone will not determine the future success of psychedelic-assisted therapies. Questions surrounding affordability, accessibility, practitioner training, reimbursement, clinic economics, pharmaceutical manufacturing and investment capital will ultimately influence how these treatments become integrated into mainstream healthcare.
As the publisher of Psychedelics.Media, organisers believe understanding the business of psychedelics is just as important as understanding the science.
For founders, investors, healthcare operators and industry leaders, PRS27 will provide an opportunity to explore the commercial realities and opportunities shaping the sector’s future.
A Meaningful Weekend of Learning and Connection
While PRS27 has been intentionally designed as a focused one-day symposium, organisers recognise that some of the most valuable conversations often occur outside formal presentations.
To support deeper engagement between delegates, speakers, sponsors and industry stakeholders, a series of networking opportunities are being planned around the symposium.
An informal welcome gathering is expected to take place on the evening of Friday, 19 March 2027, providing an opportunity for delegates arriving from interstate and overseas to connect ahead of the main event.
On Saturday, delegates will participate in a full day of presentations, panel discussions and roundtable conversations, complemented by a dedicated networking lunch and afternoon networking drinks and canapés designed to encourage direct engagement and networking between attendees.
A private VIP Dinner will follow the symposium, bringing together speakers, sponsors, industry leaders and VIP delegates for an evening of deeper discussion focused on the future of psychedelic medicine, mental health innovation and industry development.
Additional informal networking activities are also being planned for midday Sunday, 21 March 2027, providing attendees with opportunities to continue conversations, explore potential collaborations and strengthen professional relationships formed throughout the symposium.
The vision for PRS27 extends beyond a traditional conference. It is about creating an environment where the people building the future of psychedelic medicine can connect, collaborate and contribute to the responsible growth of the industry.
Registration Now Open
Attendance at PRS27 will be intentionally limited to ensure a high-quality delegate experience and meaningful interaction between participants.
Standard Delegate Pass
- Early Bird: $495 AUD
- Full Price: $695 AUD
Student Delegate Pass
- Early Bird: $295 AUD
- Full Price: $395 AUD
VIP Delegate Pass
- Early Bird: $995 AUD
- Full Price: $1,495 AUD
VIP delegates will receive access to premium networking opportunities, VIP experiences and the exclusive VIP Dinner with speakers, sponsors and invited industry leaders.
With attendance expected from across Australia and internationally, early registration is strongly encouraged.
Event Details
Event: PRS27 | Psychedelic Roundtable Symposium 2027
Presented by: Psychedelics.Media
Main Symposium Venue: Saturday, 20 March 2027
Welcome Networking Event: Friday Evening, 19 March 2027
Informal Delegate Activities: Sunday, midday 21 March 2027
Venue: TBC Melbourne, Australia
Audience: Psychiatrists, Psychologists, Researchers, Investors, Healthcare Leaders, Biotech Executives, Academics and Policymakers
Early Bird Registration
About PRS27
The Psychedelic Roundtable Symposium 2027 (PRS27) is Australia’s premier business and leadership event focused on psychedelic medicine and mental health.
Bringing together clinicians, researchers, healthcare executives, policymakers, investors, pharmaceutical companies and emerging industry leaders, PRS27 provides a platform to explore the opportunities, challenges and future direction of psychedelic healthcare in Australia and internationally.
Through expert panels, keynote presentations, networking and industry engagement, PRS27 aims to foster meaningful connections and advance the conversation around the future of mental health treatment.
